Royal Bank of Canada
EGRX

Royal Bank of Canada’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Royal Bank of Canada’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-36,925
Closed -$138K – 7433
2024
Q3 		$138K Sell
36,925
-676
-2% -$3.23K ﹤0.01% 5116
2024
Q2 		$211K Buy
37,601
+9,445
+34% +$41.1K ﹤0.01% 4724
2024
Q1 		$147K Buy
28,156
+24,600
+692% +$135K ﹤0.01% 4942
2023
Q4 		$19K Buy
3,556
+1,694
+91% +$16.7K ﹤0.01% 6342
2023
Q3 		$29K Sell
1,862
-1,642
-47% -$29.5K ﹤0.01% 6049
2023
Q2 		$68K Sell
3,504
-1,538
-31% -$36.5K ﹤0.01% 5614
2023
Q1 		$143K Buy
5,042
+2,119
+72% +$62.9K ﹤0.01% 4885
2022
Q4 		$85K Sell
2,923
-425
-13% -$13.5K ﹤0.01% 5578
2022
Q3 		$88K Buy
3,348
+3,150
+1,591% +$116K ﹤0.01% 5393
2022
Q2 		$9K Sell
198
-654
-77% -$30K ﹤0.01% 6436
2022
Q1 		$42K Sell
852
-1,217
-59% -$58.4K ﹤0.01% 6202
2021
Q4 		$106K Buy
2,069
+930
+82% +$48.2K ﹤0.01% 5894
2021
Q3 		$64K Sell
1,139
-4,696
-80% -$231K ﹤0.01% 6012
2021
Q2 		$250K Sell
5,835
-1,742
-23% -$71.9K ﹤0.01% 4879
2021
Q1 		$317K Sell
7,577
-2,841
-27% -$132K ﹤0.01% 4567
2020
Q4 		$486K Sell
10,418
-147
-1% -$6.88K ﹤0.01% 4167
2020
Q3 		$448K Buy
10,565
+2,963
+39% +$130K ﹤0.01% 3955
2020
Q2 		$364K Sell
7,602
-601
-7% -$30K ﹤0.01% 4025
2020
Q1 		$377K Sell
8,203
-13,223
-62% -$664K ﹤0.01% 3855
2019
Q4 		$1.29M Buy
21,426
+2,370
+12% +$141K ﹤0.01% 3246
2019
Q3 		$1.08M Buy
19,056
+5,373
+39% +$302K ﹤0.01% 3287
2019
Q2 		$763K Buy
13,683
+1
+0% +$52 ﹤0.01% 3536
2019
Q1 		$690K Buy
13,682
+13,044
+2,045% +$580K ﹤0.01% 3487
2018
Q4 		$26K Sell
638
-82
-11% -$4.23K ﹤0.01% 5462
2018
Q3 		$50K Buy
720
+57
+9% +$4.32K ﹤0.01% 5239
2018
Q2 		$50K Sell
663
-5,033
-88% -$317K ﹤0.01% 5155
2018
Q1 		$301K Sell
5,696
-14,018
-71% -$815K ﹤0.01% 4055
2017
Q4 		$1.05M Sell
19,714
-39,245
-67% -$2.18M ﹤0.01% 3190
2017
Q3 		$3.52M Buy
58,959
+10,742
+22% +$650K ﹤0.01% 2249
2017
Q2 		$3.81M Buy
48,217
+42,625
+762% +$3.49M ﹤0.01% 2139
2017
Q1 		$464K Buy
5,592
+1,543
+38% +$115K ﹤0.01% 3699
2016
Q4 		$321K Sell
4,049
-10,053
-71% -$730K ﹤0.01% 4136
2016
Q3 		$987K Buy
14,102
+1,751
+14% +$97K ﹤0.01% 3107
2016
Q2 		$479K Buy
12,351
+417
+3% +$17.4K ﹤0.01% 3744
2016
Q1 		$484K Buy
11,934
+4,410
+59% +$280K ﹤0.01% 3671
2015
Q4 		$667K Buy
7,524
+5,020
+200% +$396K ﹤0.01% 3491
2015
Q3 		$186K Buy
2,504
+1,869
+294% +$155K ﹤0.01% 4387
2015
Q2 		$51K Buy
635
+135
+27% +$8.79K ﹤0.01% 5211
2015
Q1 		$21K Hold
500
– – ﹤0.01% 5339
2014
Q4 		$8K Buy
500
+200
+67% +$2.55K ﹤0.01% 5681
2014
Q3 		$4K Hold
300
– – ﹤0.01% 5696
2014
Q2 		$4K Hold
300
– – ﹤0.01% 5619
2014
Q1 		$4K Buy
+300
New +$4.07K ﹤0.01% 5625

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Royal Bank of Canada's EGRX Position: Q4 2024 in Review

Royal Bank of Canada sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 36,925 shares — an estimated $138K sold.

Royal Bank of Canada first reported a position in EGRX in Q1 2014 and held it in 43 quarters. The position peaked at $3.81M in Q2 2017. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Royal Bank of Canada reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 36,925 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $138K.
  • Royal Bank of Canada first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 43 quarters.
  • Royal Bank of Canada's Eagle Pharmaceuticals, Inc. position peaked at $3.81M in Q2 2017.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Royal Bank of Canada's 13F filing for Q4 2024, filed 14 Feb 2025.